



Edition: BP 2025 (Ph. Eur. 11.6 update)

## Mianserin Tablets

### [General Notices](#)

#### Action and use

Monoamine reuptake inhibitor; tetracyclic antidepressant.

### DEFINITION

Mianserin Tablets contain Mianserin Hydrochloride.

*The tablets comply with the requirements stated under Tablets and with the following requirements.*

#### Content of mianserin hydrochloride, $C_{18}H_{20}N_2 \cdot HCl$

90.0 to 110.0% of the stated amount.

### IDENTIFICATION

- A. Shake a quantity of the powdered tablets containing 20 mg of Mianserin Hydrochloride with 10 mL of [methanol](#), filter and evaporate the filtrate to dryness. The [infrared absorption spectrum](#) of the residue, [Appendix II A](#), is concordant with the *reference spectrum* of mianserin hydrochloride ([RS 234](#)).
- B. In the Assay, the chromatogram obtained with solution (2) shows a peak with the same retention time as that due to mianserin in the chromatogram obtained with solution (1).
- C. The residue obtained in test A yields the reactions characteristic of *chlorides*, [Appendix VI](#).

### TESTS

#### Related substances

Carry out the method for [thin-layer chromatography](#), [Appendix III A](#), using the following solutions prepared in a mixture of 1 volume of 13.5M [ammonia](#) and 4 volumes of [methanol](#).

- (1) Triturate a quantity of the powdered tablets containing 40 mg of Mianserin Hydrochloride with 2 mL of a mixture of 4 volumes of [methanol](#) and 1 volume of 13.5M [ammonia](#) and centrifuge. Use the supernatant.
- (2) Dilute 1 volume of solution (1) to 200 volumes.
- (3) Dilute 2 volumes of solution (2) to 5 volumes.

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use as the coating [silica gel](#).
- (b) Use the mobile phase as described below.
- (c) Apply 5  $\mu$ L of each solution.
- (d) Develop the plate to 15 cm.
- (e) After removal of the plate, dry in a current of cold air for 5 minutes and then expose to iodine vapour for 20 minutes.

#### MOBILE PHASE

10 volumes of [methanol](#) and 90 volumes of [dichloromethane](#).

#### LIMITS

Any [secondary spot](#) in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2) (0.5%) and not more than two such spots are more intense than the spot in the chromatogram obtained with solution (3) (0.2%).

Disregard any spot with an R<sub>f</sub> value lower than 0.15.

## ASSAY

Weigh and powder 20 tablets. Carry out the method for [gas chromatography, Appendix III B](#). Use a 0.2% w/v solution of [triphenylamine](#) in [toluene](#) as the internal standard solution.

- (1) Shake a quantity of the powdered tablets containing 60 mg of Mianserin Hydrochloride with 30 mL of 0.2M [hydrochloric acid](#) for 1 hour and filter. To 10 mL of the filtrate add 3 mL of 1M [sodium hydroxide](#) and 10 mL of internal standard solution, mix for 5 minutes, centrifuge and use the clear upper layer.
- (2) Add 3 mL of 1M [sodium hydroxide](#) and 10 mL of internal standard solution to 10 mL of a solution containing 0.2% w/v of [mianserin hydrochloride BPCRS](#) in 0.2M [hydrochloric acid](#), mix for 5 minutes, centrifuge and use the clear upper layer.

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use a fused silica column (30 m × 0.32 mm) bonded with a 0.25 µm film of [phenyl\(5\)methyl\(95\)polysiloxane](#) (HP-5 is suitable).
- (b) Use [helium](#) as the carrier gas at 1.0 mL per minute.
- (c) Use isothermal conditions maintained at 255°.
- (d) Use an inlet temperature of 280°.
- (e) Use a flame ionisation detector at a temperature of 300°.
- (f) Inject 1 µL of each solution.
- (g) Use a split ratio of 1:5.

When the chromatograms are recorded under the prescribed conditions the retention time of triphenylamine relative to mianserin (retention time about 5 minutes) is about 0.7.

#### SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (2), the [resolution](#) between the peaks due to triphenylamine and mianserin is at least 10.

#### DETERMINATION OF CONTENT

Calculate the content of C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>.HCl in the tablets using the declared content of C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>.HCl in [mianserin hydrochloride BPCRS](#).

## STORAGE

Mianserin Tablets should be protected from light.